WillItSurvive
Medical technology and health companies · United States

Verily Life Sciences

verily.com ↗

Alphabet-spun health data platform running NIH All of Us and CDC research infrastructure.

Protection under test
Assessed 22 July 2026 · Evidence as of 22 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 22 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: Pre platform free-to-paid seat conversion checkpoint
The call

Verily now runs as Verily Health Inc. with Alphabet as a minority backer, holding government research contracts while revenue and headcount shrink and Truveta and Tempus AI absorb hospital data relationships.

Verily Life Sciences builds software that organizes messy medical records and helps doctors and researchers find the right patients for studies and treatments. The company has real customers (the U.S. government uses it for major health programs) and just released a new AI platform called Pre, but its revenue has been cut in half since 2022 and it has laid off workers repeatedly, signaling trouble inside. Rivals like Truveta (backed by hospitals and Microsoft) and Tempus AI (with millions of patient records already loaded) are doing the same data-organizing and patient-matching work that used to be Verily's specialty, and big cloud companies like Amazon Web Services and Google are building these tools directly into their own products, making Verily's work easier to replace. The biggest test will be whether the U.S. government renews Verily's contracts when they come up for bid, because if those deals move to a cloud giant or a rival instead, the company loses its main proof that anyone needs to buy from it.

Why
01
AI pressure: AWS HealthLake and Google Health (cloud-native AI data harmonization). Cloud AI tools now do the cohort-matching and data harmonization work Verily used to sell as a service. Could AI do the core job? Yes, likely.
02
Bigger players: Truveta (30+ health systems, Microsoft backed) and Tempus AI (38M patient records, 4,500 hospitals). Truveta and Tempus AI own hospital data pipes directly while Verily rents access through government contracts. Could a giant copy it? Yes, easily.
03
What protects it. Operating the NIH All of Us Researcher Workbench gives Verily a government relationship rivals do not have yet.
What would change this call
NIH All of Us Workbench contract re-compete outcome. If awarded to Truveta or a hyperscaler, Verily's core government-contract traction disappears.
Pre platform paid-seat conversion by Q4 2026. Shows whether the Oct 2025 AI platform generates real enterprise revenue or stays free-tier.
Further layoffs or another Alphabet divestiture within 6 months. Would indicate continued organizational instability rather than the stabilization implied by March 2026 corporate conversion.
Key numbers
  • Revenue fell from $559M to ~$285.7M est. (2026-07)
  • Headcount down 22.8% since 2023 (2025-12)
  • Alphabet cut stake to minority in $300M round (2026-03-19)
Named risks
  • Revenue estimated to have shrunk from $559M (2022) to $285.7M (2026), signaling declining traction. Severity: high
  • Headcount down 22.8% since 2023 with recurring layoffs including 58 roles around June 2026. Severity: high
  • Core moat relies on re-competing government contracts (All of Us, CDC) rather than owned exclusive data. Severity: high
  • Ownership still settling post March 2026 round, further sale or spin-off remains plausible within 6 months. Severity: medium
  • Pre platform's free tier launch (Feb 2026) may not convert to paid enterprise revenue. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Truvetalosing toTruveta owns 30+ health system consortium data and raised $320M Series C in 2025, Verily's data access is contract based, not owned
Tempus AIlosing toTempus AI holds about 38M patient records with pipes into 4,500+ hospitals as of 2026, exceeding Verily's disclosed cohort scale
AWS HealthLake and Google CloudcontestingCloud incumbents are commoditizing data harmonization workflows historically core to Verily's business, per analyst commentary in 2026
IQVIA, Oracle, IBMcontestingCB Insights (2026-06-15) groups Verily as a Leader alongside these larger incumbents in health data analytics
Questions people ask
Is Verily Life Sciences still owned by Alphabet in 2026?
No longer a controlling stake. On March 19, 2026 Verily closed a $300M round led by Series X Capital, converting to a corporation as Verily Health, Inc., with Alphabet reduced to a significant minority investor rather than controlling owner.
Is Verily profitable?
No public profitability figures are disclosed since Verily is private. Revenue estimates show decline from $559M in FY2022 (CB Insights) to an estimated $285.7M as of July 2026 (ZoomInfo), suggesting shrinking, not growing, top line.
Has Verily had layoffs?
Yes, repeatedly. Verily cut 15% of staff (about 240 roles) in January 2023, closed its medical device program in August 2025, and TrueUp reported a 58 person layoff around June 2026. Headcount fell 22.8% from 1,580 in 2023 to about 1,219 by December 2025.
Could AI replace what Verily does?
Much of Verily's traditional work, data harmonization, curation, and cohort matching, overlaps with what frontier AI and cloud platforms like AWS HealthLake and Google Cloud are automating natively. Verily itself is racing to automate this via its own 'Verily Intelligence' tooling, launched October 2025.
Who is Verily's biggest competitor?
Truveta and Tempus AI are the closest rivals. Truveta is a 30+ health system consortium backed by Microsoft that raised $320M in a 2025 Series C, while Tempus AI holds about 38 million patient records with pipes into 4,500+ hospitals, both stronger positioned in owned data than Verily.
What is Verily's Pre platform and is it making money?
Pre is Verily's AI-native precision health platform, launched October 17, 2025, integrating data harmonization, AI tooling, and researcher analytics. Verily launched free versions of Pre Exchange and Workbench in February 2026, and no verified paid revenue figures for Pre have been disclosed as of mid 2026.
Timeline
  • 2026-03-19Verily closes $300M round, converts to corporation as Verily Health Inc, Alphabet becomes minority investor
  • 2026-02Verily launches free tiers of Pre Exchange and Workbench, gains Tradewinds Marketplace awardable status
  • 2025-12-18Verily and NVIDIA announce collaboration to accelerate precision health AI agents
  • 2025-10-17Verily launches AI-native platform Pre
  • 2025-10Google exec Heather Adkins says Alphabet is selling or spinning off Verily
  • 2025-08Verily closes its medical device program
  • 2025-01Verily sells stop-loss insurance unit Granular to Elevance
  • 2024-08Verily relocates headquarters from South San Francisco to Dallas/Coppell, Texas
  • 2024Verily closes Israel R&D operations
  • 2023-01-12Verily lays off 15% of workforce, about 240 roles
Revision history
22 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
23andMeAngelalign TechnologySharecare
More in Medical technology and health companies →
Sources